Tafenoquine is an 8-aminoquinoline drug that can be administered as a single dose; however, its recent licensing and roll-out requires quantitative G6PD testing prior to use, to identify patients with both intermediate (<70% normal activity) and severe (<30% normal activity) G6PD deficiency, in whom the drug is contraindicated [14]. This evidence concerns the gene G6PD and G6PD deficiency.